You are here: Industry Insights > CRUK

News List

Cancer Research UK reports ‘most successful financial year’ for its spinouts pharmatimes
July 16, 2021
Cancer Research UK (CRUK) has reported record levels of investment for its spinout portfolio, with the ‘most successful financial year’ recorded to date.
Cancer Research UK launches new ‘cancer tech accelerator’ programme pharmatimes
March 29, 2021
Cancer Research UK (CRUK) and Capital Enterprise have launched a new initiative for researchers to translate their ideas into innovations for cancer patients – named the cancer tech accelerator programme.
CRUK teams up with Teon to trial first-in-class cancer drug pharmaceutical-technology
March 03, 2021
Cancer Research UK (CRUK) has signed a clinical development collaboration with California-based Teon Therapeutics.
CRUK scientists develop drug that targets KRAS pathways pharmatimes
January 05, 2021
A new study, funded by Cancer Research UK (CRUK) and Wellcome, has discovered a new way to target the KRAS mutation, which is found in a number of hard-to-treat cancer types.
CRUK researchers develop new early-stage rectal cancer treatment pharmatimes
December 14, 2020
Cancer Research UK (CRUK) researchers have developed a new treatment for early-stage rectal cancer which they say could provide patients with an improved quality of life.
CRUK, Latus and Edinburgh Uni launch test camostat for COVID-19 pharmatimes
June 01, 2020
Cancer Research UK and its partners have kicked off a clinical trial to determine the potential of repurposing a drug used to treat inflammation of the pancreas for the treatment of COVID-19.
Crescendo links with CRUK to progress cancer therapy pharmatimes
May 06, 2020
Crescendo Biologics and Cancer Research UK have entered into a Clinical Development Partnership to progress one of Crescendo’s novel bispecific Humabody immunotherapies, CB213, into clinical trials targeting cancers of high unmet medical need.
CRUK partners with Vaccitech on NSCLC immunotherapeutic vaccine pharmaceutical-technology
December 19, 2019
Vaccitech has signed a partnership with Cancer Research UK (CRUK) to clinically advance VTP-600, the former’s immunotherapy vaccine candidate, for patients with non-small cell lung cancer (NSCLC).
CRUK and Owlstone launch trial for cancer breath test pharmaphorum
January 04, 2019
Cancer Research UK and Owlstone Medical have launched a clinical trial to develop a breath test that could detect cancer at an early stage – the first test of its kind to investigate multiple cancer types.....
CR UK forms £30m partnership with EU cancer charities pharmatimes
September 27, 2018
Cancer Research UK is partnering with European cancer research charities AIRC (Associazione Italiana per la Ricerca sul Cancro) and FC AECC (Asociación Española Contra el Cáncer) to invest around £30 million...

Previous page 1 2 Next page